Abstract Not all biomarkers are equal, and some arguably should not be classified as biomarkers at all. Despite an explosion in putative biomarker discoveries from high-throughput proteomic technologies, very few advance beyond initial excitement to become validated, clinically actionable tools. Most stall in a biomarker ‘valley of death’, where promising signals fail to meet robust […]
A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-busting with unicorn biomarkers.
July 25, 2026
J Hepatol